What Are the Treatment Options for SIRVA?
Once SIRVA is suspected, a practical question follows: How should it be treated?
The answer depends on what was actually injured.
A patient with acute subacromial bursitis should not necessarily receive the same treatment as a patient with adhesive capsulitis, focal rotator cuff pathology, synovitis, or a structural tendon injury.
This distinction is important because SIRVA describes the relationship between a shoulder syndrome and vaccine administration, it does not identify a single anatomical diagnosis.
A useful treatment principle is therefore:
Treat the shoulder pathology that is present, while considering whether the clinical course is consistent with a vaccine-administration-related injury.
There Is No Established SIRVA-Specific Treatment Protocol
The treatment literature remains limited. Wiesel and Keeling concluded that the optimal treatment of SIRVA remained unclear because of the limited number of cases and incomplete understanding of its pathophysiology. They identified NSAIDs, physical or occupational therapy, and corticosteroid injections as the mainstays of reported nonsurgical treatment.
Similarly, the updated systematic review by MacMahon and colleagues found that the most commonly reported treatments were physical/occupational therapy, NSAIDs or other nonnarcotic analgesics, and corticosteroid injections. Surgery was generally reserved for patients with persistent symptoms despite nonsurgical treatment.
Most importantly, the available literature does not contain randomized trials comparing SIRVA treatment strategies.
Thus, treatment recommendations are largely extrapolated from the management of the underlying shoulder pathology.
Step One: Determine What Is Being Treated
Before selecting treatment, the clinician should identify the predominant pain generator or pathology.
Depending on the presentation, this might include:
subacromial/subdeltoid bursitis,
adhesive capsulitis,
rotator cuff tendinopathy,
focal tendon injury,
glenohumeral synovitis,
biceps tenosynovitis,
bone or periosteal injury,
or neurologic injury.
MRI and ultrasound may help define these abnormalities, but imaging findings must be correlated with the examination and clinical history.
This is particularly important because MRI frequently identifies preexisting or incidental pathology. Wiesel and Keeling emphasize that imaging can help identify concomitant conditions and guide treatment, but it cannot itself establish a causal relationship between vaccination and the visualized pathology.
NSAIDs and Other Analgesic Treatment
Anti-inflammatory medication is one of the most commonly reported initial treatments. In the Hesse analysis of 476 conceded SIRVA claims:
50.4% received NSAIDs or other analgesics and
27.3% received oral corticosteroids.
Wiesel and Keeling similarly reported NSAID use in approximately half of patients in the larger SIRVA datasets.
NSAIDs may be particularly reasonable when the presentation appears predominantly inflammatory, such as acute bursitis or tendinopathy. But the literature does not demonstrate that NSAIDs alter the natural history of SIRVA itself.
They should therefore be understood primarily as symptom-directed treatment for the underlying inflammatory shoulder condition.
Physical Therapy
Physical or occupational therapy is probably the most frequently reported SIRVA treatment. In Hesse's 476-case VICP cohort:
381 patients, or 80%, underwent physical or occupational therapy.
Systematic reviews likewise identify physical therapy as one of the most common treatment modalities. But “physical therapy” is not a single treatment.
The appropriate rehabilitation strategy depends on the diagnosis.
A patient with: bursitis or rotator cuff pain may benefit from progressive restoration of motion, scapular mechanics, and rotator cuff loading.
A patient with: adhesive capsulitis may require a program focused more heavily on restoring capsular mobility and maintaining range of motion.
A patient with: significant acute inflammation may initially tolerate aggressive stretching or strengthening poorly.
Thus, therapy should be pathology-specific and stage-specific rather than automatically prescribing the same protocol to every patient labeled with SIRVA.
Why Avoiding Prolonged Immobilization May Matter
This is particularly relevant for adhesive capsulitis. Foong and colleagues proposed that post-vaccination pain can lead to prolonged disuse of the shoulder and that immobilization, together with underlying inflammation, may contribute to the development or progression of adhesive capsulitis.
This provides a rationale for maintaining appropriate shoulder motion when tolerated.
It does not mean that painful shoulders should simply be forced through aggressive rehabilitation.
The balance is between:
protecting an acutely inflamed shoulder and
avoiding unnecessary prolonged immobilization.
Corticosteroid Injections
Corticosteroid injections are also frequently reported. In the Hesse cohort:
60.1% received at least one shoulder corticosteroid injection.
Reported targets include:
subacromial/subdeltoid bursa,
glenohumeral joint,
and other pathology-specific locations.
The target should ideally correspond to the clinical diagnosis. For example:
predominant subacromial bursitis → subacromial injection whereas
adhesive capsulitis/synovitis → glenohumeral injection may be more appropriate.
This is preferable to treating “SIRVA” generically without identifying the structure responsible for symptoms.
Does Early Corticosteroid Injection Improve Outcomes?
There is some intriguing, but low-level, evidence suggesting that early corticosteroid treatment may be beneficial.
Macomb and colleagues published a small case series specifically examining early corticosteroid injections for SIRVA. Later reviews noted that patients treated with corticosteroid injection within approximately five days of vaccination had rapid symptom resolution.
However, these observations come from small uncontrolled reports. They do not establish that every suspected SIRVA patient should receive an immediate corticosteroid injection or that early injection is superior to other treatments.
The evidence is hypothesis-generating rather than definitive.
Ultrasound Guidance Can Add Precision
When an injection is performed, ultrasound guidance can help ensure that medication is delivered to the intended structure.
This is potentially useful in SIRVA because imaging may reveal multiple abnormalities.
Ultrasound can also permit:
dynamic examination
sonopalpation
targeted diagnostic anesthetic injection
immediate reassessment of symptoms.
That can help answer:
Which structure is actually producing the patient's pain?
But, as discussed in the imaging section of the site, a positive diagnostic injection helps establish localization, not causation.
Adhesive Capsulitis Requires a Different Approach
When adhesive capsulitis is the predominant clinical phenotype, treatment should generally follow principles used for conventional frozen shoulder.
Foong and colleagues treated post-vaccination adhesive capsulitis with physiotherapy and intra-articular hydrodilatation and reported improvement in both pain and range of motion.
Their review identifies nonsurgical options including:
physiotherapy, oral analgesics, corticosteroid injection, and hydrodilatation.
For refractory cases, manipulation under anesthesia or arthroscopic capsular release may be considered.
This illustrates why identifying the specific SIRVA phenotype matters. Hydrodilatation is a treatment for capsular restriction, not for SIRVA generically.
Hydrodilatation
Hydrodilatation has appeared in several post-vaccination adhesive capsulitis reports.
The procedure involves image-guided distention of the glenohumeral capsule, generally using fluid together with anesthetic and often corticosteroid, with the goal of improving capsular mobility.
The available SIRVA evidence consists largely of case reports and small series. It therefore supports hydrodilatation as a reasonable pathology-directed treatment for adhesive capsulitis, not as a proven SIRVA-specific intervention.
What About Rotator Cuff Pathology?
Rotator cuff findings require careful interpretation because tears and tendinopathy may predate vaccination.
If the cuff abnormality appears clinically relevant, treatment generally follows standard principles for rotator cuff disease. Zeldin and colleagues summarize this concept well: treatment for the specific injury after vaccine administration is generally unchanged from the standard treatment for that underlying shoulder pathology.
That might include:
activity modification,
NSAIDs,
rehabilitation,
targeted injection,
and, in selected structural lesions, surgical treatment.
But before treating a degenerative cuff tear surgically, it is particularly important to determine whether that tear is actually the pain generator.
Wiesel and Keeling caution that preexisting pathology may be aggravated in some cases but that surgery should not be directed automatically at abnormalities simply because they appear on MRI.
Diagnostic Injections Can Help Before Escalating Treatment
This is one area where diagnostic injections may be particularly useful. Suppose MRI shows:
partial supraspinatus tearing + AC arthritis + labral degeneration + bursitis.
Which finding should be treated? A carefully targeted anesthetic injection may help determine whether symptoms localize to:
the subacromial space,
glenohumeral joint,
AC joint,
or another region.
Wiesel and Keeling specifically describe diagnostic lidocaine injections as useful for differentiating potential sources of pain in this population.
Again, the response establishes clinical relevance of the target, not the cause of the underlying pathology.
What About PRP or Other Orthobiologics?
These treatments have occasionally been mentioned in the SIRVA literature, but the evidence is extremely limited.
One clinical review mentions regenerative injections such as platelet-rich plasma among treatments that have been used for pathology-specific management. However, there is currently insufficient SIRVA-specific evidence to recommend PRP as an established treatment for SIRVA itself.
If PRP is considered, the rationale would need to arise from the underlying tendon or musculoskeletal diagnosis, not simply from the presence of a SIRVA history.
This is an important distinction between treating SIRVA and treating a tendon disorder in a patient with suspected SIRVA.
What About Ultrasound-Guided Tenotomy or Debridement?
This is another emerging area with limited evidence. Bodor, Uribe, and Srikumaran reported five patients with chronic vaccination-related shoulder dysfunction who underwent ultrasound-based localization followed by ultrasonic aspiration and debridement.
Their approach used ultrasound, sonopalpation, and diagnostic anesthetic injection to identify focal pathology before treatment.
Our subsequent 2026 case series similarly used ultrasound findings and targeted diagnostic anesthetic injections to select patients with chronic refractory symptoms for ultrasound-guided tenotomy, vacuum aspiration, and debridement.
These reports suggest a potential option for a highly selected subgroup with focal chronic pathology after failure of conservative treatment.
They do not establish minimally invasive tenotomy or debridement as standard treatment for SIRVA.
When Is Surgery Considered?
Surgery is generally reserved for patients with:
persistent symptoms
a clearly identified treatable pathology
failure of appropriate nonsurgical management.
The updated systematic review by MacMahon and colleagues found that surgery was generally used only after nonsurgical treatment failed.
Reported procedures include:
subacromial decompression,
bursectomy,
synovectomy,
arthroscopic debridement,
lysis of adhesions,
capsular release,
manipulation under anesthesia,
and rotator cuff repair.
However, the indication should be based on the underlying pathology, not simply on persistent pain following vaccination.
The Hesse VICP dataset reported surgery in: 155 of 476 patients — 32.6%.
Among those surgical patients, reported procedures included subacromial decompression, joint debridement, rotator cuff repair, diagnostic arthroscopy, manipulation under anesthesia, lysis of adhesions, bursectomy, distal clavicle excision, synovectomy, and labral repair.
That does not mean one-third of all patients with SIRVA require surgery.
The cohort consisted of conceded compensation claims, creating substantial selection bias toward patients with more severe and persistent symptoms.
Systematic reviews of the broader literature report considerably lower surgical utilization in some populations. MacMahon et al., for example, found surgery rates ranging from approximately 3% in one larger study to higher proportions in selected smaller series.
This is why study population matters.
What Does the Surgical Literature Actually Show?
The evidence is mostly case based. Wong and colleagues reported arthroscopic treatment after conservative management failed. They described debridement of inflamed soft tissue and bone followed by postoperative physical therapy, with substantial improvement.
Other reports have described:
bursectomy,
synovectomy,
capsular procedures,
and treatment of structural tendon pathology.
These cases demonstrate that surgery can be effective in selected refractory patients.
They cannot determine which patients should undergo surgery or whether surgery is superior to continued nonsurgical management.
Infection Must Not Be Missed
Not every severe shoulder reaction following vaccination is sterile inflammatory SIRVA.
Rare cases of septic arthritis and other infections have been reported following injections.
This distinction is critical because suspected infection may require:
aspiration,
cell count,
Gram stain,
culture,
inflammatory laboratory testing,
and potentially urgent surgical management and antibiotics.
A painful, swollen shoulder with fever, systemic illness, substantial effusion, or other concerning features should not simply be labeled “SIRVA” without evaluating infection.
Treatment for infectious complications is fundamentally different from treatment for sterile inflammatory SIRVA.
Treatment Response Does Not Prove Causation
This point is particularly important for medical-legal review. Suppose a patient improves dramatically after a subacromial corticosteroid injection.
That supports the conclusion that the subacromial space was an important pain generator.
It does not prove:
the vaccine caused the bursitis.
Similarly, improvement after capsular hydrodilatation supports adhesive capsulitis as an important component of the syndrome.
Improvement after rotator cuff surgery supports the clinical relevance of the treated cuff pathology.
None of those treatment responses independently establishes etiology.
Is Earlier Treatment Better?
Possibly, but the evidence is not strong enough to make a definitive statement.
Small case reports suggest favorable outcomes after early corticosteroid injection.
Early restoration of appropriate shoulder motion may also theoretically reduce progression toward adhesive capsulitis.
But no randomized trial has established:
early injection versus delayed injection,
injection versus physical therapy, or
one injection target versus another for SIRVA.
Therefore, statements that delayed treatment necessarily caused chronic SIRVA should be made cautiously.
A Practical Treatment Framework
Rather than a single SIRVA protocol, the current literature supports a pathology-directed approach:
Predominant problem | Treatments described in the literature |
Bursitis/inflammatory pain | Activity modification, NSAIDs, PT, targeted corticosteroid injection |
Adhesive capsulitis | PT, glenohumeral corticosteroid injection, hydrodilatation; selected refractory cases may require capsular procedures |
Rotator cuff tendinopathy | Activity modification, rehabilitation, NSAIDs, selected injections |
Focal chronic tendon pathology | Pathology-specific treatment; limited case evidence for image-guided debridement |
Structural rotator cuff tear | Standard cuff management based on tear characteristics, symptoms, age, function, and chronicity |
Synovitis | Anti-inflammatory treatment and targeted intra-articular therapy; evaluate competing inflammatory/infectious causes |
Suspected infection | Aspiration/cultures and infection-specific treatment rather than routine SIRVA management |
Refractory structural pathology | Selected surgical or minimally invasive intervention |
This is a clinical framework derived from the published literature, not a validated SIRVA treatment algorithm.
The Bottom Line
What is the best treatment for SIRVA?
There is no single answer.
The strongest theme across the literature is:
Treat the pathology—not simply the label.
Most patients reported in the literature have initially
References
Wiesel BB, Keeling LE. Shoulder injury related to vaccine administration. J Am Acad Orthop Surg. 2021;29(17):732-739.
Hesse EM, Atanasoff S, Hibbs BF, et al. Shoulder Injury Related to Vaccine Administration (SIRVA): petitioner claims to the National Vaccine Injury Compensation Program, 2010-2016. Vaccine. 2020;38(5):1076-1083.
Macomb CV, Evans MO, Dockstader JE, Montgomery JR, Beakes DE. Treating SIRVA early with corticosteroid injections: a case series. Mil Med. 2020;185(1-2):e298-e300.
Pettyjohn EW, Clugston JR, Zaremski JL. Shoulder injury related to vaccine administration and a growing challenge: a focused review. Curr Sports Med Rep. 2022;21(3):78-83.
Wong W, Barnes LA, Williams D, et al. Arthroscopic surgical management of shoulder secondary to shoulder injury related to vaccine administration (SIRVA): a case report. JSES Rev Rep Tech. 2021 Jun;30(6):e334-e337.
Foong BCM, Ho SWL, Tan LTJ, Lee KT, Jegathesan T. Adhesive capsulitis secondary to COVID-19 vaccination: a case series. Malays Orthop J. 2023;17(2):43-48.
Biglia A, Morandi V, Zanframundo G, Donati D, Maggiore F, Vita F, et al. Adhesive capsulitis after COVID-19 vaccine injection: a peculiar case treated with combined bursa distention and glenohumeral capsular hydrodilatation. J Ultrasound. 2023. Dec;26(4):909-911.
Bodor M, Montalvo E. Vaccination-related shoulder dysfunction. Vaccine. 2007;25(4):585-587.
Bodor M, Uribe Y, Srikumaran U. Ultrasonic aspiration for vaccination-related shoulder dysfunction. Heliyon. 2021;7(11):e08442.
Sussman WI, Davitt K, Mitchell K, Sussman J, Latzka E. Sonographic features of Shoulder Injury Related to Vaccine Administration: a case series. Clin J Sport Med. 2026.
Zeldin R, et al. Shoulder pain after influenza vaccine administration: a clinical vignette. Am J Phys Med Rehabil. 2023 Oct 1;102(10):e141-e143.
Atanasoff S, Ryan T, Lightfoot R, Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine. 2010;28(51):8049-8052.
Wood CT, Ilyas AM. Shoulder injury related to vaccine administration: diagnosis and management. J Hand Surg Glob Online. 2022;4:111-117.
Marshall T, Addison M, Crawford NW, Buttery JP, Cheng DR. Aiming too high: Shoulder injury related to vaccine administration (SIRVA): a case series. Vaccine. 2022;40(52):7505-7509.
MacMahon A, Nayar SK, Srikumaran U. What Do We Know About Shoulder Injury Related to Vaccine Administration? An Updated Systematic Review. Clin Orthop Relat Res. 2022 Jul 1;480(7):1241-1250.
Comments